Wells Fargo raises Regeneron stock price target to $925 on execution

Wells Fargo raised its Regeneron price target to $925 from $750 but kept an Equal Weight rating; the new target is slightly below the cited share price of $927.89, after a 14.88% weekly rally. The firm cited strong commercial execution and sees roughly $83 per share in 2027 earnings, implying about 11x earnings versus the current P/E of 22.72. Separately, Regeneron reported Q3 2026 non-GAAP EPS of $20.07 and revenue of $5.12 billion, up 70% and 36% year over year, respectively; management said the gross-to-net benefit contributing to Dupixent revenue growth should not be expected in Q4 or 2027.

Analysis

The key underwriting issue is earnings quality, not the headline growth rate. The cited 340B gross-to-net benefit appears nonrecurring: management reportedly does not expect it in Q4 or 2027. If investors extrapolate that uplift, the near-term earnings base will overstate the run rate; focus instead on underlying Dupixent patient demand and volume after mix effects. The reported IQVIA script measure may understate volume, but that needs corroboration in subsequent company disclosures.

The quoted 2027 P/E is highly sensitive to delivering the $83 EPS estimate and is not directly comparable with a trailing multiple. At the current price—already above Wells Fargo’s revised target after a sharp weekly move—the risk/reward for chasing is unattractive unless estimates continue to rise. The Eylea HD review and long-acting IL-13 progress could support sentiment, but each is a catalyst to verify, not a guaranteed source of multiple expansion. Failure to resolve the review or evidence of weaker underlying demand would challenge the bullish case. Sanofi participates in the Dupixent collaboration, but the article does not establish how incremental product growth translates into its reported earnings.

Over 1–3 months, watch REGN guidance and demand metrics for evidence that growth persists without the 340B benefit. Over 6–18 months, the thesis turns on pipeline execution and Eylea HD competitiveness; continued share pressure or delayed development progress would undermine the premium earnings narrative. Competitors’ products may intensify the commercial burden, but the article provides no share data to quantify that exposure.

Key Decisions for Investors

• Do not chase REGN after the rally. Consider trimming or waiting for a better entry; the cited target is below the prevailing share price, while the near-term upside case requires further estimate revisions.
• For existing exposure, track reported Dupixent volume and gross-to-net trends separately. Treat the 340B benefit as nonrecurring unless management later provides evidence it persists; a slowdown in underlying demand would falsify the growth thesis.
• Keep Eylea HD review status and long-acting IL-13 milestones on a catalyst watchlist. Reassess only when there is verifiable resolution or clinical progress; delays, adverse outcomes, or weaker guidance would argue against multiple expansion.